One study found significant overexpression of NLRP3 in the inflamed gut of SKG mice, and treatment of SKG mice with mcc950, an NLRP3 antagonist, prior to induction of inflammatory disease inhibited the development of intestinal disease and delayed the onset of joint inflammation (106). This evidence concerns the gene NLRP3 and intestinal disorder.